How many medicines do patients with heart failure need?

Circulation

Volumn 103, Issue 12, 2001, Pages 1611-1612

  Parmley, W W ^a  

^a UCSF Medical Center at Parnassus   (United States)

Author keywords

Editorials; Heart failure; Remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; LOOP DIURETIC AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE OVERLOAD; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0035957285     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.12.1611     Document Type: Editorial

References (16)

1. The effect of digoxin on mortality and morbidity in patients with heart failure
2. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scan-dinavia Enalapril Survival Study (CONSENSUS)
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
5. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
6. The effect of spironolactone on morbidity and mortality in patients with sever heart failure
7. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
8. Plasma cytokine parameters and mortality in patients with chronic heart failure
9. The role of tumor necrosis factor in the pathophysiology of heart failure
10. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
11. Results of targeted anti-TNF therapy with Etanercept (ENBREL) in patients with advanced heart failure
12. β-Adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling
13. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implication for clinical trials
14. Effect of oral milrinone on mortality in severe chronic heart failure
15. Effects of vesnarinone on morbidity and mortality in patients with heart failure
16. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure